In glaucoma, preclinical studies targeting neuroprotection have attempted to overcome limitations regarding long-term expression of the neurotrophic factor BDNF and safety issues from off-target effects of antiapoptotic proteins. This evidence concerns the gene BDNF and glaucoma.